Mammalian hibernation is a unique and potent strategy for survival in winter when food and water are not available. Our hypothesis is that some of the mechanisms utilized for protection against the stress in winter, might also be used to protect ischemic myocardium, even though hibernating mammals do not have coronary artery disease or myocardial ischemia. The focus of this proposal is to examine the woodchucks' protection in winter against complete coronary artery occlusion and its consequences of remodeling and the development of heart failure. After a complete occlusion of a coronary artery the major mechanism that can ameliorate the effects of ischemia relate to the coronary vessels and development of angiogenesis, which is supported by the preliminary data in this application. Our preliminary data also indicate that vascular stiffness and the composition of vessels are altered in winter thereby permitting enhanced blood flow. Potential cellular mechanisms include cAMP response element-binding protein (CREB) and nitric oxide synthase (NOS). It is important to keep in mind that these studies will be conducted for the first time in a natural model of cardioprotection, quite different from traditional studies in experimental animal models or genetically altered mice. Our Hypothesis: Woodchucks prepare for winter by developing mechanisms that extensively modify their blood vessels resulting in reduced vascular stiffness and induction of new coronary vessels, which provide blood flow to the ischemic heart and attenuate heart failure development and remodeling after chronic, complete coronary artery occlusion.

Public Health Relevance

Coronary artery disease and myocardial ischemia are the leading causes of death and disability in the U.S. population. Almost all new therapies are derived from experimental animal models or genetically altered mouse models. This proposal is unique, in that it is the first to study a natural model of animal hibernation, which protects the animals as winter approaches, but also develops novel mechanisms to protect against myocardial ischemia.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL130848-02
Application #
9206183
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
Schwartz, Lisa
Project Start
2016-01-15
Project End
2019-12-31
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Rutgers University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
078795851
City
Newark
State
NJ
Country
United States
Zip Code
07103
Zhang, Jie; Levy, Daniel; Oydanich, Marko et al. (2018) A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion. J Mol Cell Cardiol 121:13-15
Vatner, Dorothy E; Zhang, Jie; Oydanich, Marko et al. (2018) Enhanced longevity and metabolism by brown adipose tissue with disruption of the regulator of G protein signaling 14. Aging Cell :e12751
Zhao, Zhenghang; Kudej, Raymond K; Wen, Hairuo et al. (2018) Antioxidant defense and protection against cardiac arrhythmias: lessons from a mammalian hibernator (the woodchuck). FASEB J 32:4229-4240
Guers, John J; Gwathmey, Judith; Haddad, Georges et al. (2017) Minority investigators lack NIH funding. Science 356:1018-1019
Guers, John J; Zhang, Jie; Campbell, Sara C et al. (2017) Disruption of adenylyl cyclase type 5 mimics exercise training. Basic Res Cardiol 112:59
Zhang, Jie; Zhao, Xin; Vatner, Dorothy E et al. (2016) Extracellular Matrix Disarray as a Mechanism for Greater Abdominal Versus Thoracic Aortic Stiffness With Aging in Primates. Arterioscler Thromb Vasc Biol 36:700-6
Vatner, Stephen F (2016) Why So Few New Cardiovascular Drugs Translate to the Clinics. Circ Res 119:714-7
Jose Corbalan, J; Vatner, Dorothy E; Vatner, Stephen F (2016) Myocardial apoptosis in heart disease: does the emperor have clothes? Basic Res Cardiol 111:31
Bravo, Claudio A; Vatner, Dorothy E; Pachon, Ronald et al. (2016) A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion. J Pharmacol Exp Ther 357:331-6